INTRODUCTION
Protein C is a serine protease zymogen that has been isolated from bovine (1-3) and human plasma (4, 5) . Activated protein C is a potent anticoagulant that shows remarkable species specificity (3, 4, 6, 7) and it is identical to autoprothrombin 1I-A (7, 8) . Purified activated bovine protein C inactivates purified bovine Factor Va (9-11) and Factor VIII:C (12) and it destroys Factor Xa binding sites and prothrombinase activities of washed bovine platelets (13, 14) . When human activated protein C is added to human plasma, it selectively inactivates Factors V and VIII (5) .
Because plasma proteases are usually regulated by plasma protease inhibitors, we sought to identify the existence of an inhibitor for activated protein C. Once we found that normal plasma inhibited activated protein C, we theorized that patients lacking this inhibitor might present with an apparent deficiency of Dr. Marlar is the recipient of fellowships from the American Heart Association and the National Institutes of Health. Dr. Griffin , to whom reprint requests should be addressed, is recipient of a National Institutes of Health Research Career Development Award (National Heart, Lung, and Blood Institute-00192).
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1186 both Factor V and Factor VIII:C, since activated protein C readily destroys both these factors in plasma (5) . Indeed, a very rare form of hemophilia in which patients are deficient in both Factors V and VIII:C has been known for 26 yr (15, 16 Kisiel (4) . The fractions from this column that contained protein C were pooled and subjected to preparative polyacrylamide gel electrophoresis as described elsewhere for the purification of Factor X.I Purified protein C appeared greater than 95% homogenous on polyacrylamide gels in the presence of sodium dodecyl sulfate and reducing agent and the protein elicited a monospecific antiserum upon injection into a goat.
Protein C was activated by a-thrombin-Sepharose. 200 1l of thrombin-Sepharose that had been washed exhaustively with Tris-buffered saline, 0.01 M Tris-Cl, 0.15 M NaCl, pH 7.4, was added to 3 ml of protein C (29,ug/ml) in Tris-buffered saline. The activation of protein C was followed by the appearance of hydrolytic activity against the chromogenic substrate, S-2238.
In the spectrophotometric assay, 60,lA of the sample was added to 600 Al of 0.1 mM S-2238 in 0.05 M Tris-Cl, 0.1 M NaCl, pH 8.3. The increase in A40Jmin was determined using a Gilford recording spectrophotometer. Maximal activity was observed within 60 min, at which time the thrombin-Sepharose was removed by centrifugation. Activated protein C was stored in frozen aliquots at -70'C and it retained full activity for at least 6 mo. Activated protein C inhibitory activity in plasma was assayed by measuring the ability of plasma to inhibit the amidolytic activity of the enzyme against S-2238 (4, 5). In the assay, 150 Al of plasma, 100 ,lI of activated protein C (1 ,tg/ml), 50 Al ofheparin (35 U/ml final concentration), and 50 1L of anti-prekallikrein gamma globulin (21) were incubated at 37°C. At various times a 60-1 aliquot was removed, mixed with 600 1i. of S-2238 and assayed for hydrolysis of the substrate.
The heparin and anti-prekallikrein antibodies were found useful in reducing the background amidolytic activities of plasma proteases.
To determine if the inhibitor of activated protein C was a protein, 400 i1. of trypsin-Sepharose was incubated with 1 ml of partially purified inhibitor that was obtained by dialyzing fractions obtained from chromatography of plasma on DEAESephadex A-50 (22) . For this trypsinisation, all reactants were in Tris-buffered saline. The reaction proceded for 2 hat 370C and then trypsin-Sepharose was removed by centrifugation. Aliquots of activated protein C were then incubated with inhibitor aliquots that were either exposed or unexposed to trypsin-Sepharose. After 30 min at 37°C, the residual activated protein C activity was determined using the S-2238 hydrolysis assay. Plasma (3 liters) was fractionated on DEAE-Sephadex A-50 (14 x 50 cm column) at 200C with elution by an increasing salt, decreasing pH gradient as previously described (22) . 2-ml aliquots from various column fractions were dialyzed against Tris-buffered saline overnight at 40C and assayed for inhibitory activity against activated protein C. The elution positions of known plasma protease inhibitors were determined using double immunodiffusion analysis with commercial antisera.
The elution positions of a,-macroglobulin, Cl-inhibitor, antithrombin III, and a,-antiplasmin were independently verified by the fact that each of these inhibitors has been purified in our laboratory from pools of fractions from similar columns.2 I Marlar, R. A., A. J. Kleiss, and J. H. Griffin. Reevaluation of the extrinsic system of blood coagulation. Submitted for publication. 2 Griffin, Kleiss, and Miles. Unpublished observation. (Fig. 1A) . Activated protein C activity was reduced to 0-25% of its original value within 30 min. However, activated protein C was not inhibited by four combined Factor VNVIII-deficient plasmas from four unrelated patients (Fig. 1A) ; even after 30 min no detectable (+ 10%) inhibition occurred. The ability of Factor V-deficient plasmas and Factor VIII-deficient plasmas to inhibit activated protein C was indistinguishable from that of normal plasma (Fig. 1B) . Thus, the absence of inhibitory activity was unique to the plasmas from patients with inherited combined Factor V/VIII deficiency.
RESULTS

Inhibition
In preliminary experiments, the presence of calcium ions and phospholipid either alone or together had no Protein C Inhibitor Deficiency in Combined Factor VIVIII Deficiency 1 187 significant effect on the inhibitory activity of normal plasma.
To determine if anything in the combined Factor V/VIII-deficient plasmas might adversely affect the normal protein C inhibitor, normal plasma was diluted with Factor V/VIII-deficient plasma or with buffer before assaying the inhibition of activated protein C. The results (Fig. 2) show that nothing in the combined Factor V/VIII-deficient plasma altered the ability of normal plasma to neutralize activated protein C. Between 0 and 8% normal plasma, a linear dose-response relationship was observed in the inhibition assay (Fig.  2) . This establishes a quantitative assay for the inhibition of activated protein C and the data indicate that -12% normal plasma (150 ,ul) neutralizes 100 ,ul of 1 ,ug/ml of activated protein C. Moreover, since the assay is sensitive to 2% normal plasma, the observation of no detectable inhibition (±+10%) by the combined Factor V/VIII-deficient plasmas after 30 min (Fig. 1A) implies there is <2% of the inhibitor in the patient's plasma.
Commercial Factor VIII concentrate and Factor IX concentrate from one manufacturer were assayed for their ability to inhibit activated protein C. Neither one contained detectable inhibitory activity. In other assays, the supernatant of barium-adsorbed plasma was found to contain a normal level of the inhibitor of activated protein C.
Fractionation of protein C inhibitor on DEAESephadex. To define some of the properties of the protein C inhibitor, normal plasma was fractionated on DEAE-Sephadex. One major region of activity that inhibited activated protein C was found. The inhibitor activity eluted at the beginning of the gradient just behind the bulk of gamma globulins but before any beta globulins such as plasminogen or Factor XII. The known plasma protease inhibitors, a,-antitrypsin, al- antichymotrypsin, a2-macroglobulin, Cl-inhibitor, antithrombin III, and a,-antiplasmin, were eluted much later than the inhibitor of activated protein C. No overlap of the protein C inhibitor activity and the known plasma inhibitors was seen. Moreover, assays of the fractions from the DEAE-Sephadex column showed that activated protein C was not inhibited by any of the known plasma inhibitors. To determine if the protein C inhibitory activity was protein in nature, trypsin-Sepharose was assessed for its ability to destroy the inhibitory activity of partially purified inhibitor. Partially purified inhibitor was obtained by dialyzing a pool of fractions obtained from a DEAE-Sephadex column. The inhibitory activity was not lost from the pool of activity during dialysis implying that the inhibitor is a macromolecule. Exposure of the partially purified inhibitor to trypsinSepharose destroyed 81% of the inhibitor activity. In controls, the inhibitor incubated with buffer lost none (±10%) of its activity. Thus, it appears that the inhibitor of activated protein C is a protein because it is not dialyzable and is destroyed by trypsin.
DISCUSSION
The results of this study show that normal plasma contains an inhibitor of activated protein C. This inhibitor elutes from DEAE-Sephadex at low ionic strength at pH 8.4 just after most gamma globulins and it is entirely separated from all known plasma protease inhibitors on this column. The This work was supported in part by research grants from the National Institutes of Health, National Heart, Lung, and Blood Institute-24891, and from the California chapter of the American Heart Association.
